Seneca Biopharma's receivables is $0.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (December 2020), SNCA shows a receivables of $0. That compares with $21K in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, SNCA's receivables is now $0 (was $21K) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Seneca Biopharma is outperforming or lagging.
Tracking SNCA's receivables over time shows whether Seneca Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $21K in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has Seneca Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.
Seneca Biopharma's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.